NEJM publishes daraxonrasib results for advanced pancreatic cancer
Updated
Updated · NBC News · May 6
NEJM publishes daraxonrasib results for advanced pancreatic cancer
14 articles · Updated · NBC News · May 6
The study of 168 metastatic patients found 8.1 months progression-free survival and 15.6 months overall survival at the highest dose after prior chemotherapy.
Revolution Medicines' drug has FDA fast-track status and expanded access, while Phase 3 data showed 13.2 months survival with daraxonrasib plus chemotherapy versus 6.7 months with chemotherapy alone.
Doctors called the findings a major advance against a cancer usually diagnosed late; severe side effects affected about 30% of patients, and researchers are also testing the drug in colorectal and lung cancers.
Can a drug that doubles survival but causes severe side effects in most patients truly improve quality of life?
As this pill moves to first-line trials, can it replace chemotherapy as the new standard of care for pancreatic cancer?
With multiple 'undruggable' cancer drugs emerging, what makes this one the potential $7 billion winner in a high-stakes race?
Revolution Medicines’ Daraxonrasib Shows Unprecedented 13.2-Month Survival in Metastatic Pancreatic Cancer
Overview
In May 2026, Revolution Medicines announced groundbreaking Phase 3 trial results for daraxonrasib, an oral KRAS inhibitor, showing a median overall survival of 13.2 months—nearly double that of standard chemotherapy—and a 60% reduction in mortality risk for metastatic pancreatic cancer patients. Daraxonrasib’s unique mechanism targets active RAS proteins across diverse mutations, leading to broad clinical effectiveness and a manageable safety profile. These compelling results prompted the FDA to authorize an expanded access program and accelerated regulatory submissions, with potential approval expected by late 2026. This breakthrough is reshaping treatment for pancreatic cancer and driving changes in clinical practice to optimize patient care.